Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
University of Michigan |
---|---|
Information provided by: | University of Michigan |
ClinicalTrials.gov Identifier: | NCT00150995 |
Purpose: The aim of this clinical trail is to evaluate Tetrathiomolybdate (TM) in the treatment of hormone refractory prostate cancer.
Condition | Intervention | Phase |
---|---|---|
Prostate Cancer |
Drug: tetrathiomolybdate |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment |
Official Title: | A Phase II Trail of Tetrathiomolybdate in Patients With Hormone Refractory Prostate Cancer |
Estimated Enrollment: | 37 |
Study Start Date: | May 2001 |
Tetrathiomolybdate or TM, a drug developed for Wilson's Disease, removes copper from the bloodstream. Copper is a key factor in angiogenesis (blood vessel growth)- a process that occurs normally in the body but becomes uncontrolled in cancerous cells. Tetrathiomolybdate essentially wages war against copper, which serves to choke off tumor growth. Realizing the key role of copper in angiogenesis, researchers have begun exploring treatment with Tetrathiomolybdate for different types of cancers. This clinical trial will evaluate the effectiveness of Tetrathiomolybdate in the treatment of patients with hormone refractory prostate cancer. Hormone refractory prostate cancer refers to advanced disease in which the patient no longer responding to conventional hormonal treatment.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Patients must have histologic diagnosis of adenocarcinoma of the prostate with progression following hormonal therapy and antiandrogen withdrawal.
United States, Michigan | |
The University of Michigan Comprehensive Cancer Center | |
Ann Arbor, Michigan, United States, 48109 |
Principal Investigator: | David C. Smith, MD | The University of Michigan Comprehensive Cancer Center |
Study ID Numbers: | UMCC 9962 |
Study First Received: | September 6, 2005 |
Last Updated: | September 6, 2005 |
ClinicalTrials.gov Identifier: | NCT00150995 |
Health Authority: | United States: Food and Drug Administration |
Tetrathiomolybdate Prostatic Diseases Genital Neoplasms, Male Molybdenum |
Urogenital Neoplasms Genital Diseases, Male Prostatic Neoplasms |
Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Growth Substances Physiological Effects of Drugs Trace Elements Enzyme Inhibitors Angiogenesis Inhibitors Pharmacologic Actions |
Neoplasms Neoplasms by Site Therapeutic Uses Micronutrients Angiogenesis Modulating Agents Growth Inhibitors Chelating Agents |